The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation : EITOS Study of GETECCU
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural history of pre-existing IBD and de novo IBD after SOT.
METHODS: This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was IBD progression, defined by escalation of medical treatment, surgical therapy, or hospitalization due to refractory IBD. Risk factors were identified using multivariate Cox proportional hazard analysis.
RESULTS: A total of 177 patients (106 pre-existing IBD and 71 de novo IBD) were included. Most patients with pre-existing IBD (92.5%) were in remission before SOT. During follow-up, 32% of patients with pre-existing IBD had disease progression, with a median time between SOT and IBD progression of 2.2 (interquartile range, 1.3-4.6) years. In the de novo cohort, 55% of patients had disease progression with a median time to flare of 1.9 (interquartile range, 0.8-3.9) years after diagnosis. In the pre-existing IBD cohort, active IBD at the time of SOT (hazard ratio, 1.80; 95% confidence interval, 1.14-2.84; P = .012) and the presence of extraintestinal manifestations (hazard ratio, 3.10; 95% confidence interval, 1.47-6.54; P = .003) were predictive factors for IBD progression.
CONCLUSIONS: One-third of patients with pre-existing IBD and about half of patients with de novo IBD have disease progression after SOT. Active IBD at the time of SOT and the presence of extraintestinal manifestations were identified as risk factors for IBD progression.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Inflammatory bowel diseases - (2024) vom: 22. März |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
Flare |
---|
Anmerkungen: |
Date Revised 22.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1093/ibd/izae041 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370076818 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370076818 | ||
003 | DE-627 | ||
005 | 20240323235955.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240323s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/ibd/izae041 |2 doi | |
028 | 5 | 2 | |a pubmed24n1343.xml |
035 | |a (DE-627)NLM370076818 | ||
035 | |a (NLM)38518109 | ||
035 | |a (PII)izae041 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bastón-Rey, Iria |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation |b EITOS Study of GETECCU |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 22.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a BACKGROUND: Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural history of pre-existing IBD and de novo IBD after SOT | ||
520 | |a METHODS: This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was IBD progression, defined by escalation of medical treatment, surgical therapy, or hospitalization due to refractory IBD. Risk factors were identified using multivariate Cox proportional hazard analysis | ||
520 | |a RESULTS: A total of 177 patients (106 pre-existing IBD and 71 de novo IBD) were included. Most patients with pre-existing IBD (92.5%) were in remission before SOT. During follow-up, 32% of patients with pre-existing IBD had disease progression, with a median time between SOT and IBD progression of 2.2 (interquartile range, 1.3-4.6) years. In the de novo cohort, 55% of patients had disease progression with a median time to flare of 1.9 (interquartile range, 0.8-3.9) years after diagnosis. In the pre-existing IBD cohort, active IBD at the time of SOT (hazard ratio, 1.80; 95% confidence interval, 1.14-2.84; P = .012) and the presence of extraintestinal manifestations (hazard ratio, 3.10; 95% confidence interval, 1.47-6.54; P = .003) were predictive factors for IBD progression | ||
520 | |a CONCLUSIONS: One-third of patients with pre-existing IBD and about half of patients with de novo IBD have disease progression after SOT. Active IBD at the time of SOT and the presence of extraintestinal manifestations were identified as risk factors for IBD progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a flare | |
650 | 4 | |a inflammatory bowel disease | |
650 | 4 | |a solid organ transplantation | |
700 | 1 | |a Rodríguez-Lago, Iago |e verfasserin |4 aut | |
700 | 1 | |a Luque, Ana María |e verfasserin |4 aut | |
700 | 1 | |a Caballol, Berta |e verfasserin |4 aut | |
700 | 1 | |a Soutullo-Castiñeiras, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Bravo, Ana |e verfasserin |4 aut | |
700 | 1 | |a Castaño, Andrés |e verfasserin |4 aut | |
700 | 1 | |a Gros, Beatriz |e verfasserin |4 aut | |
700 | 1 | |a Bernal, Lorena |e verfasserin |4 aut | |
700 | 1 | |a Diz-Lois, María Teresa |e verfasserin |4 aut | |
700 | 1 | |a Alonso-Galán, Horacio |e verfasserin |4 aut | |
700 | 1 | |a Cañete, Fiorella |e verfasserin |4 aut | |
700 | 1 | |a Castro, Beatriz |e verfasserin |4 aut | |
700 | 1 | |a Pérez-Galindo, Pablo |e verfasserin |4 aut | |
700 | 1 | |a González-Muñoza, Carlos |e verfasserin |4 aut | |
700 | 1 | |a El Hajra, Ismael |e verfasserin |4 aut | |
700 | 1 | |a Martínez-Montiel, Pilar |e verfasserin |4 aut | |
700 | 1 | |a Alonso-Abreu, Inmaculada |e verfasserin |4 aut | |
700 | 1 | |a Mesonero, Francisco |e verfasserin |4 aut | |
700 | 1 | |a González-Vivo, María |e verfasserin |4 aut | |
700 | 1 | |a Peries, Laia |e verfasserin |4 aut | |
700 | 1 | |a Martín-Arranz, Eduardo |e verfasserin |4 aut | |
700 | 1 | |a Abril, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Marín-Jiménez, Ignacio |e verfasserin |4 aut | |
700 | 1 | |a Baltar, Ruth |e verfasserin |4 aut | |
700 | 1 | |a Vicuña, Miren |e verfasserin |4 aut | |
700 | 1 | |a Moreno, Nadia |e verfasserin |4 aut | |
700 | 1 | |a Brunet, Eduard |e verfasserin |4 aut | |
700 | 1 | |a Rubín de Célix, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Fajardo, Ingrid |e verfasserin |4 aut | |
700 | 1 | |a Cruz, Noelia |e verfasserin |4 aut | |
700 | 1 | |a Calvino-Suárez, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Rojas-Feria, María |e verfasserin |4 aut | |
700 | 1 | |a Fernández-Clotet, Agnes |e verfasserin |4 aut | |
700 | 1 | |a Gimeno-Torres, Marta |e verfasserin |4 aut | |
700 | 1 | |a Nieto-Garcia, Laura |e verfasserin |4 aut | |
700 | 1 | |a de la Iglesia, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Zabana, Yamile |e verfasserin |4 aut | |
700 | 1 | |a Suárez-Ferrer, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Barreiro de Acosta, Manuel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g (2024) vom: 22. März |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izae041 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 22 |c 03 |